Analyst Ratings February 9, 2026

Bernstein Maintains Outperform on Zillow After Court Ruling, Keeps $95 Target

Favorable preliminary injunction ruling eases legal overhang as analysts diverge ahead of imminent earnings

By Avery Klein ZG
Bernstein Maintains Outperform on Zillow After Court Ruling, Keeps $95 Target
ZG

Bernstein has reaffirmed an Outperform rating and a $95.00 price target on Zillow Group (ZG) following a favorable ruling tied to the company’s dispute with Compass. The decision, which allows Zillow to continue applying its listing rules, arrives just ahead of the company’s Feb. 10 earnings report and comes amid mixed analyst positioning and recent downward pressure on the stock.

Key Points

  • Bernstein reiterated an Outperform rating on Zillow with an unchanged $95.00 price target following a favorable preliminary injunction ruling in the company’s dispute with Compass - impacts the Real Estate and Legal sectors.
  • Zillow shares are trading at $54.60, materially below the 52-week high of $90.22, and recent market data show the stock is down 11.74% over one week and 29.69% over six months - relevant to equity investors and technology-focused funds.
  • Analyst responses are mixed: Evercore ISI also holds an Outperform and $95.00 target, KeyBanc cut its target to $75.00 while keeping Overweight, and Barclays moved to Equalweight with a $72.00 target - reflecting divergent views within the sell-side covering the broader technology and real estate marketplaces.

Bernstein reiterated an Outperform rating for Zillow Group (ZG) and left its price target unchanged at $95.00 after a court granted a favorable preliminary injunction in Zillow’s legal dispute with Compass. Zillow shares are trading at $54.60, well below the 52-week high of $90.22.

The legal outcome - a ruling on the preliminary injunction - is being viewed by Bernstein as a constructive development for Zillow. The firm said the decision helps remove a stream of legal headlines that have weighed on Zillow’s valuation multiple and could reduce the potential spread of Private Listings, a competitive concern that had raised questions about Zillow’s access to inventory and the strength of its moat.

Bernstein’s note emphasized two primary implications of the ruling: first, it begins to clear the company of legal uncertainty that has contributed to compression in valuation multiples; second, it may slow the proliferation of Private Listings that had been identified as a risk to Zillow’s inventory pipeline. The research house did not forecast specific near-term earnings outcomes but expressed a constructive view on Zillow’s 2026 prospects and described the current share price as an attractive entry point.

Market data show Zillow’s stock has come under recent pressure. InvestingPro metrics cited by analysts indicate the shares slipped 11.74% over the past week and are down 29.69% over six months, with technical indicators suggesting oversold conditions. Despite the decline, InvestingPro also reports Zillow is trading near its Fair Value and offers additional insights and a comprehensive research report on the company.

Analysts outside Bernstein presented a range of views in recent coverage. Evercore ISI maintained an Outperform rating and likewise set a $95.00 price target, projecting that intra-quarter data and Zillow’s historical performance point to modest upside versus expectations for the upcoming fourth-quarter 2025 earnings report. KeyBanc adjusted its price target lower to $75.00 from $90.00, citing a general decrease in technology sector multiples while retaining an Overweight stance. Barclays upgraded Zillow to Equalweight and raised its target to $72.00, citing stronger execution and anticipated revenue and EBITDA growth.

On the balance sheet front, analysts note Zillow’s financial position remains solid, with more cash than debt. Street projections compiled by analysts point to an expectation that the company will reach profitability this year.

The legal ruling also included a separate judicial decision allowing Zillow to continue its listing rules in the face of the challenge brought by Compass Inc. That ruling is part of the broader legal backdrop that has influenced investor sentiment and valuation metrics for the stock in recent months.

With the company set to report earnings on Feb. 10, the immediate focus for investors and analysts will be how the legal news factors into guidance, revenue trends, and margin dynamics. Bernstein’s reaffirmation of an Outperform rating and its unchanged $95.00 target underscores the firm’s continued conviction in Zillow’s fundamental outlook despite recent share-price weakness and legal headwinds.


Contextual note - InvestingPro is referenced as a source of data and analytical coverage used by market participants evaluating Zillow’s valuation and technical condition.

Risks

  • Legal and regulatory uncertainty - ongoing litigation and challenges to Zillow’s listing rules have compressed valuation multiples and could continue to affect investor sentiment and sector pricing dynamics; this primarily impacts the Real Estate and Legal sectors.
  • Broader technology sector headwinds - a general reduction in tech multiples has already led to lower analyst targets and could limit upside for Zillow despite positive legal news, affecting technology-focused equity portfolios and growth-oriented funds.
  • Earnings and execution risk - while analysts expect profitability this year, upcoming quarterly results (scheduled for Feb. 10) and intra-quarter performance could deviate from expectations, influencing revenue and EBITDA projections across the digital real estate segment.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026